LY3463251 is the first GDF-15 receptor agonist to complete a Phase I clinical trial, with results showing an average weight reduction of 3% in patients after 12 weeks of treatment
Tirzepatide degrades when exposed to heat, so standard shipping may save money upfront, but if your medication sits in a hot truck for six hours, you've paid for a product that no longer works as intended
When experiencing gastrointestinal side effects, oral rehydration solutions containing electrolytes may be beneficial
And then the sad part is those are the kids that become, I believe, much more susceptible to ultimately heading into autism spectrum
Most of that nausea is mild to moderate and concentrated in the first few weeks of each dose escalation
Do your symptoms get worse, stay the same, or improve with activity